AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: It also reduces BCR-ABL expression in K562 cells (a CML model cell line) and modulates the PTEN/PI3K/Akt signaling pathway, promoting apoptosis and impairing cell survival [31].